Evosep develops a standardized liquid chromatography platform to enable clinical applications of proteomics, aiming to unlock LC‑MS for drug discovery and clinical diagnostics. Its platform offers high sample throughput and reproducibility between runs and across instruments and sites, producing useable data for panels with multiple protein biomarkers. The company plans to use new funding to advance clinical applications of proteomics and to expand its global presence, particularly in the U.S. Evosep was founded in 2016 by proteomics technology pioneer Ole Vorm and is led by CEO Christian Ravnsborg. The business focuses on standardizing proteomics for clinical use and on developing clinically meaningful protein‑based diagnostics. The platform’s emphasis on throughput and cross‑site reproducibility underpins its strategy to enable widespread clinical deployment of proteomics.

Total raised

$40M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2023